BASEL,
Switzerland, Nov. 1
/PRNewswire/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB:
MRES).
In the first "Update to Shareholders," we
advised shareholders of the Company's new direction as well as the
list of licensed products ready to be manufactured and
distributed.
Subsequently, we revealed the description of
two "Blood Tests" by first releasing a scientific account and
analysis followed by a "layman's" version with explanations for
common understanding.
We have also informed the public, based on
official statistics, of the commercial potential of the SymPath
test in the American market.
It is now the time to disclose the work done
since the first "Update to Shareholders."
Neuro-Biotech has to date, signed
confidentiality agreements with various interested parties,
including a Spanish group representing the vast majority of
hospitals and private clinics in Spain. This group has shown a particular
appreciation for the distribution of all our blood tests. Seeing
that there is language and historical ties, all private clinics and
private hospitals located in South
America will be automatically granted access.
Now if you review the list of licenses your
company owns, you will notice that the last four licenses (13, 14,
15, 16), are what we call Neuroceuticals™. It's actually tablets to
be sold in pharmacies, that will be classified and sold as "food
supplements," in order to accelerate the market penetration. There
will be two concentrations; one sold "over the counter," and the
other with a medical prescription.
This fact is mentioned due to the ongoing actual
negotiations with another Spanish party that controls networks of
pharmacies across the country and in South America. Very soon, similar negotiations
will open with large chains of pharmacies in the United States and Canada.
We already have on hand a first order from
Egypt, and we expect to conclude
and receive other sales orders in the near future. The
manufacturing of these tablets do not require significant capital
investments such as laboratories. Fabrication will be assigned to a
pharmaceutical company, already identified, responding to all our
criteria and quality standards. As for cost, it remains for us to
agree on the quantities to achieve economies of scale.
Regarding our "Blood Tests," we also started
preliminary discussions with chains of laboratories, in order to
first, identify, evaluate and explore potential partnerships. This
will avoid us having to invest in our own lab facilities in the
short and medium term while ensuring the production of blood test
results for health professionals to track their patients. This is
exactly the same principle as a blood test ordered by your doctor
to know your cholesterol levels.
We also solicited and were contacted by various
insurance companies about "SymPath." This test has been the subject
of numerous scientific publications and has been evaluated in over
5,000 human subjects with consistent results of 98.8% precision.
With this accuracy, the results could be enough to obtain a legal
court opinion on a patient's medical status.
The reason why insurance companies have
expressed such a considerable interest is economic. As this test
accurately measures the patient's condition on a scale, it avoids
the sequences of "trial and error," as is currently the case in the
beginning of treatment. Therefore, the health professional
receiving the test results will immediately be able to precisely
diagnose the patient's condition and to prescribe the proper
medication.
The immediate consequences, as you can imagine,
will be a dramatic reduction of suffering for the patient, his
family, his environment and accelerated healing. From a purely
economic and social development standpoint, this will certainly
lead to a significant reduction in lost workdays, and fewer
payments from insurers and employers! Currently, without this test,
it is virtually impossible for medical professional specializing in
this type of disease, to separate the real from the fake patients.
The whole of society will benefit from this.
The Company will continue to provide its
shareholders and investors with timely updates.
For more information, do not hesitate to contact
us by using the form on our corporate website at
neuro-biotechcorp.com. Your request will be transferred to the
appropriate person and we will get back to you as soon as
possible.
Forward Looking Statements
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
CONTACT:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
Copyright v. 1 PR Newswire